Dr. Agarwal’s Eye Hospital Ltd Q2FY26 | 36% Profit Surge, 31% Margins & A Vision That’s Sharper Than Its Share Price
1. At a Glance
Move aside, LASIK. The only real vision correction we need is looking at Dr. Agarwal’s Q2FY26 numbers. The Chennai-based chain of ophthalmic hospitals seems to have applied laser precision to its quarterly results — revenue at ₹118 crore (up 15% YoY), profit after tax ₹19.3 crore (up 36.5%), and operating margins at a clean 31.3%. At a market cap of ₹2,500 crore and a P/E of 39.7, this “eye con” of healthcare might just be India’s best prescription for steady compounding.
The stock trades at ₹5,173 (30 Oct close), giving investors a mild case of eye-watering valuation — 7.95x book value to be precise. Still, when you’re delivering 29.5% ROE and 17.5% ROCE, who needs eye drops? The company’s return over 3 months has been 16.8%, over 6 months 20.7%, and over 3 years a solid 58.8%. Promoter holding? A clear 72.7% — though 29.3% of that is pledged, like your friend’s gold chain at Muthoot.
So here we are: a smallcap hospital chain that’s growing faster than the population of Chennai, with a balance sheet that’s part clinic, part compounder, and a promoter who just injected ₹70 crore more via preferential allotment at ₹5,270 per share. The question is — are they expanding, or are they just buying more eye drops for all that pledge stress?
2. Introduction
Imagine a business where people voluntarily show up, pay high margins, and thank you while leaving — that’s Dr. Agarwal’s Eye Hospital Ltd (AEHL) for you. Born in Tamil Nadu but now spreading like WhatsApp forwards across India, AEHL is proving that eye care can be as profitable as it is noble.
Over the last few years, this company has turned “focus” into a literal business strategy. Cataract surgeries? 83% of its service revenue. Vision centers? 36 new ones just in FY24. Surgeons? 205 of them — up from 155 in FY22. It’s an assembly line of eyeballs and efficiency.
But here’s the twist — while the listed AEHL (market cap ₹2,500 crore) handles the Tamil Nadu-heavy operations, the real big brother, Dr. Agarwal’s Health Care Ltd (DAHCL), is the family office of lenses, controlling 180 facilities across India and Africa. DAHCL recently raised $80 million from Temasek and TPG Growth to expand to 300+ centers. Translation? The family business sees opportunity everywhere — even in your myopia.
Now with 29% ROE and 30% profit growth, AEHL stands out among hospital peers for its scalpel-sharp metrics. Yet the market yawns with a “just” 39x P/E, while Apollo trades at 71x and Max at 95x. Maybe investors are squinting too much to notice.
3. Business Model – WTF Do They Even Do?
Let’s decode AEHL’s business model — think of it as your eye in Excel format:
a) Sale of Services (~76%) – This includes all those cataract, glaucoma, retina, and laser correction procedures. Surgeries alone make up 83% of this segment, with treatments & investigations contributing 12%, and consultations 5%. In short, this is not an “eye check-up” business — it’s a high-margin surgical operation machine.
b) Sale of Products (~24%) – The side hustle of vision: opticals (64%), pharmaceuticals (33%), and contact lenses/accessories (3%). It’s basically the Apple Store of eyeballs — fix your lens, then upsell the frame.
The company has cleverly expanded into tier-2 and tier-3 towns with small “Dr. Agarwal’s Eye Clinic” centers feeding bigger surgical hubs. In FY24 alone, it launched 36 vision centers and 6 surgical centers. That’s expansion with both precision and patience.
And just to flex, AEHL is constructing a flagship Center of Excellence in Gopalapuram, Chennai — a temple of corneas where every specialty sits under one roof.
But hold on — the promoter entity DAHCL is in the same business. So, what’s happening here? It’s like your cousin opening another biryani shop with the same name down the street. Thankfully, the recent board approval (Aug 2025) aims to merge AEHL back into DAHCL in a 23:2 share swap. Translation: the family is reuniting — hopefully before more pledges happen.
4. Financials Overview
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue
₹118 Cr
₹102 Cr
₹117 Cr
15.2%
0.9%
EBITDA
₹37 Cr
₹30 Cr
₹32 Cr
23.3%
15.6%
PAT
₹19.3 Cr
₹14.1 Cr
₹17.0 Cr
36.5%
13.5%
EPS (₹)
39.98
30.11
36.72
33%
9%
EBITDA margins are sitting at a clean 31% — Apollo Hospitals is jealous. Profit margins? A healthy 16%. The company has been compounding revenue at 25% CAGR and profit at 31% over 3 years. That’s not eye care, that’s wealth care.
5. Valuation Discussion – Fair Value Range Only
Let’s zoom into valuations before our eyes glaze over:
P/E Method: Annualized EPS = 39.98 × 4 = ₹159.9. At the current price ₹5,173, implied P/E = 32.3x (matches reported 39.7x because of TTM variance). If we assume a justified P/E band of 35x–45x for a 25% compounder, Fair Value Range = ₹5,600 – ₹7,200.
EV/EBITDA Method: EV = ₹2,827 Cr, EBITDA (FY25) = ₹134 Cr → EV/EBITDA = 21x. Peer average (Apollo 27x, Max 28x, Fortis 23x). At
